Abstract:Objective To study the expression of vasculogenic mimicry (VM)and matrix metalloproteinase(MMP)-2 in endometrial carcinoma (EC)tumor tissue and their clinical relationship with EC.Methods A total of 52 EC patients at the Jinan Military General Hospital from October 2010 to December 2013 were selected as EC group, which underwent hysterectomy and had complete clinical data. Another 21 cases over the same period as control group, which had hysterectomy because of the uterine fibroids or other benign diseases.Furthermore,12 cases of pathological findings diagnosed as atypical endometrial hyperplasia(EIN)patients were selected as EIN group.Endometrial paraffin-embedded sections of all patients were taken for the study.All of the paraffin-embedded sections adopted staining of CD34 and periodic acid-schiff (PAS)together,and observed the expression of VM in three groups,while the paraffin-embedded sections of EC group were stained by immunohistochemistry streptavidin-perosidase (SP)in order to observe the expression of MMP-2.The differences of the positive expression rates of VM and the high expression rates of MMP-2 in different clinical factors among 52 cases of EC patients,including age,International Federation of Gynecology and Obstetrics(FIGO)clinical stages,World Health Organization(WHO) pathological differentiated grading,the infiltrating depth of muscular layer and whether had lymph node metastasis,were statistically analyzed.Meanwhile,the correlation between the expression of VM and MMP-2 in EC group were analyzed.This study followed the Ethical Standards of the Human Trials Committee of the Jinan Military General Hospital, had the approval of the commission. Informed consent was obtained from each participant.There were no significant differences among three groups in general clinical data,such as the age,menopause,childbearing history,menstrual history,etc.(P >0.05 ).Results ①The positive rate of VM in the tumor tissue of EC group was 30.8%(1 6/52),but did not find VM express in endometrium in control group and EIN group.②The positive expression rate of VM in stageⅠpatients of FIGO was lower than that of stage Ⅲ-Ⅳ(14.3%vs 70.0%), and the difference was statistically significant (P = 0.002 ); WHO pathological differentiated grading between well,moderately and poorly differentiation of the EC patients had pairwise comparisons,showed the higher level of differentiation had a lower VM positive expression rate than the lower level of differentiation,and the differences were statistically significant(P <0.05);The VM positive expression rate in patients with lymph node metastasis was higher than that in patients without lymph node metastasis (66.7% vs 23.3%),and the difference was statistically significant (χ2 =4.704,P =0.030);There were no significant differences of VM positive expression rate between ≤ 50 years and > 50 years old patients,between patients with infiltrating depth of muscular layer <1/2 and ≥1/2 (P > 0.05 ).③ The high expression rate of MMP-2 in patients with lymph node metastasis was higher than that in patients without lymph node metastasis (88.9% vs 23.2%),and the difference was statistically significant (χ2 = 1 1.413,P = 0.000 );There were no significant differences of high expression rate of MMP-2 between patients ≤50 years and >50 years old,among FIGO clinical stageⅠ,Ⅱ and Ⅲ-Ⅳ,among WHO pathological differentiated grading of well,moderately and poorly,between the infiltrating depth of muscular layer < 1/2 and ≥ 1/2 (P >0.05).④The correlation of expression level of VM and MMP-2 were positively correlated in the 52 cases tumor tissue in EC group(r =0.478,P =0.000).Conclusions VM exists in some EC tissues and was related to the severity of EC.MMP-2 may promotes the formation of VM.Both of VM and MMP-2 may together promote the lymph node metastasis of EC patients.

Association of insulin-like growth factor II mrna-binding protein 3 (IMP3) expression with prognostic and morphological factors in endometrial cancer

Protein disulfide isomerase A3 as novel biomarker for endometrial cancer

Expression of Insulin-Like Growth Factor- II Mrna-Binding Protein 3 in Colon Cancer and Its Implication

Prognostic impact of CD133 expression in Endometrial Cancer Patients

IMP3 Is a Novel Prognostic Marker that Correlates with Colon Cancer Progression and Pathogenesis

Clear Cell Carcinomas of the Ovary: a Mono-Institutional Study of 73 Cases in China with an Analysis of the Prognostic Significance of Clinicopathological Parameters and IMP3 Expression

Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification

The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations

Eukaryotic Initiation Factor 3B is Overexpressed and Correlates with Larger Tumor Size, Advanced FIGO Stage, and Shorter Overall Survival in Epithelial Ovarian Cancer Patients.

Immunohistochemical Analysis Of Novel Biomarkers Cyclin D1, p53 And Ki67 In Endometrial Carcinoma: Clinicopathological Significance And Prognostic Value

Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma

The Prognostic Significance of Eukaryotic Translation Initiation Factors (eIFs) in Endometrial Cancer

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Relationships Between the Molecular Biomarkers and the Clinicopathologic Features and Prognosis in Endometrial Carcinoma

Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options

Clinical Implications and Prognostic Value of Five Biomarkers in Endometrial Carcinoma

Prognostic molecular biomarkers in endometrial cancer: A review

Elevated expression of ECT2 as a diagnostic marker and prognostic indicator in endometrial cancer

TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma

Expression of Vasculogenic Mimicry and Matrix Metalloproteinase-2 in Endometrial Carcinoma

Preoperative prediction of poor prognostic parameters and adjuvant treatment in women with pure endometrioid type endometrial cancer: what is the significance of tumor markers?